Shots:

• Under the agreement, if Lilly will lead the clinical development & commercialization then Abbisko will receive ~$258M upon achievement of prespecified preclinical, clinical development & commercial milestones along with royalties & if Abbisko will responsible then Lilly will receive milestones along with royalties 
• The collaboration combines Abbisko’s drug discovery platform with Lilly's expertise to develop novel molecules against an undisclosed target for cardiometabolic diseases
• If Abbisko boosts the compounds, Lilly will get the right to develop & commercialize the product. If Lilly did not advance the compounds then Abbisko will get the right for the product

Ref: PR Newswire | Image: Crunchbase